SLC5A2 and hydrops fetalis: For every 1000 patients treated for one year, allocation to an SGLT-2 inhibitor in patients with HFrEF was estimated to prevent 7 first kidney disease progression (unadjusted for differences in definitions) and 6 serious AKI events, 39 HF hospitalizations, and 11 cardiovascular deaths, and cause 0.6 amputations.